ADMA Biologics Inc logo

ADMA Biologics Inc

$ 3.24 -0.12 (-3.57%) 04:00 PM EST
P/E:
At Loss
P/B:
6.35
Market Cap:
$ 637.56M
Enterprise V:
$ 778.99M
Volume:
2.40M
Avg Vol (2M):
2.84M
Volume:
2.40M
Market Cap $:
637.56M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.84M
Enterprise Value $:
778.99M
PB Ratio:
6.35
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Name Current Vs Industry Vs History
Cash-To-Debt 0.23
Equity-to-Asset 0.33
Debt-to-Equity 1.52
Debt-to-EBITDA -3.27
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.36
Distress
Grey
Safe
Beneish M-Score -2.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 66.42
9-Day RSI 65.38
14-Day RSI 64.01
6-1 Month Momentum % 32
12-1 Month Momentum % 94.12

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.04
Quick Ratio 1.38
Cash Ratio 0.79
Days Inventory 473.64
Days Sales Outstanding 64
Days Payable 55.44

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -61.7

Financials (Next Earnings Date:2023-03-24 Est.)

ADMA's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:ADMA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 130.481
EPS (TTM) ($) -0.37
Beta 0.45
Volatility % 35.07
14-Day RSI 64.01
14-Day ATR ($) 0.169454
20-Day SMA ($) 3.0965
12-1 Month Momentum % 94.12
52-Week Range ($) 1.17 - 3.47
Shares Outstanding (Mil) 196.78

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ADMA Biologics Inc Filings

Document Form Filing Date
No Filing Data

ADMA Biologics Inc Analysis

Share your research

Headlines

See More
No news.